J C Lindow
Affiliation: University of Vermont
- Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humansJanet C Lindow
Vaccine Testing Center and Unit of Infectious Diseases, Department of Medicine, University of Vermont College of Medicine, Burlington, Vermont, United States of America
PLoS Negl Trop Dis 6:e1742. 2012..This work provides an initial framework for defining primary T cell responses to each DENV serotype and will enhance the evaluation of a tetravalent DENV vaccine...
- Caught in the act: in vivo development of macrolide resistance to Campylobacter jejuni infectionJ C Lindow
Vaccine Testing Center, University of Vermont College of Medicine, Department of Medicine, Burlington, VT 05405, USA
J Clin Microbiol 48:3012-5. 2010..In vivo development of macrolide resistance may be an important contributor to antibiotic resistance in C. jejuni...
- Antibodies in action: role of human opsonins in killing Salmonella enterica serovar TyphiJanet C Lindow
University of Vermont College of Medicine, Department of Medicine, Vaccine Testing Center and Unit of Infectious Diseases, Burlington, VT 05405, USA
Infect Immun 79:3188-94. 2011..Typhi. Future work could lead to improved immunogenicity tests associated with vaccine efficacy and the identification of correlates of protection against typhoid fever...
- In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming unitsC E Lyon
The University of Vermont College of Medicine, Burlington, VT 05405, USA
Vaccine 28:3602-8. 2010..Typhi-specific LPS IgG and 83.3-97.4% IgA; 92.1% had a positive S. Typhi LPS ELISPOT. M01ZH09 is safe and immunogenic up to 1.7 x 10(10)CFU. Efficacy testing of this single-dose oral typhoid vaccine is needed...